Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by Barclays PLC

Barclays PLC grew its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 152.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 75,052 shares of the specialty pharmaceutical company's stock after buying an additional 45,291 shares during the quarter. Barclays PLC owned 0.23% of Collegium Pharmaceutical worth $2,899,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Pacer Advisors Inc. grew its stake in Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company's stock valued at $109,749,000 after acquiring an additional 821,541 shares during the period. Rubric Capital Management LP lifted its holdings in Collegium Pharmaceutical by 27.2% during the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company's stock valued at $75,139,000 after purchasing an additional 499,473 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after purchasing an additional 64,958 shares during the period. Renaissance Technologies LLC increased its position in shares of Collegium Pharmaceutical by 8.0% during the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company's stock worth $49,314,000 after purchasing an additional 113,300 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Collegium Pharmaceutical by 2.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,039,024 shares of the specialty pharmaceutical company's stock valued at $33,457,000 after purchasing an additional 19,876 shares during the last quarter.

Collegium Pharmaceutical Stock Down 0.3 %

NASDAQ COLL traded down $0.09 during trading hours on Wednesday, hitting $29.06. 121,120 shares of the company were exchanged, compared to its average volume of 449,669. The company has a 50 day moving average of $32.12 and a two-hundred day moving average of $34.27. The firm has a market cap of $937.19 million, a price-to-earnings ratio of 12.53 and a beta of 0.80. Collegium Pharmaceutical, Inc. has a 52-week low of $28.75 and a 52-week high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. HC Wainwright raised their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research note on Thursday, September 5th. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.